METANOMIC
18.5.2022 09:32:04 CEST | Business Wire | Press release
Today, Metanomic (https://www.metanomic.net/ ) announces it has acquired Intoolab A.I (https://www.intoolab.com/ ) , a Bayesian Network Artificial Intelligence company, to expand and to improve data analysis and A.I across video games and Web3. This acquisition augments Metanomic’s current game economy infrastructure that allows developers to build, simulate and run balanced game economies and core gameplay loops in a live, real-time environment.
The addition of artificial intelligence helps developers create better experiences through intelligent insight from player behaviour in run-time. As a part of the acquisition the existing solution will be rebranded to Thunderstruck and extend the capabilities of the Metanomic Engine.
A more intelligent approach to video game development and Web3 analytics
Thunderstruck is based on a new approach to artificial intelligence that is not based on off the shelf machine learning algorithms but a powerful combination of Deep Learning and Dynamic Bayesian Networks. The solution has already been successfully proven in Healthcare and the technology is now being applied initially to video games and Web3 in a number of core applications -
- Web 3 Intelligence relating to game and NFT discovery and recommendation for tailored and personalized results to the user or player
- Game Economy Intelligence providing Economy Balance Prediction, Gamer Categorisation, Gameplay Recommendations, Retention Strategies and NPC Intelligence
- Ad Categorization delivers analytics around player and consumer classification both on and off-chain for in-game advertising networks to drive more personalized results
- DeFI Intelligence providing on and off-chain user profiling for DeFi insight into asset purchases and income for new products and services, reputation scoring and more.
“Web3 and metaverse are the next big thing that will affect our everyday lives in so many dimensions and we couldn’t be at a better place and time with our technology, to take the next step and introduce Dynamic Bayesian Networks to this untapped and exciting new market,” said Nikos Tzagkarakis , CEO and Co-founder of IntooLab who joins Metanomic as their incoming Chief AI Officer.
“We knew from the first time we met Theo and the rest of the team, that joining the incredible Metanomic powerhouse is our best bet to be part of an unmatched platform for Web3, game economies and the metaverse.
“The incredible traction we’ve seen across both the traditional games industry, web3, and play-and-earn games for the beta of our economy platform already puts us in a strong position to help developers build more fun and engaging experiences,” Theo Priestley, CEO of Metanomic said.
"With the acquisition of an artificial intelligence platform we can deliver more power to developers through real-time player insight as well as the most advanced game economy solution in the industry.”
With the acquisition also comes the commitment to continue to build the company’s development hub in Greece, supporting the local startup community and tech economy.
Thunderstruck is available for trial and partner integration from today. The Metanomic Engine is a complete, free to use game economy design and run-time solution for game developers across Web3 and traditional games and is currently in a closed beta. To sign up for the waiting list email hello@metanomic.net
About Metanomic
Metanomic is the first and only complete real-time economy as a service platform for developers. Built by professional economists and game designers, the platform utilizes patented algorithms to easily deploy plug and play, interoperable and infinitely scalable game and creator economies ready for web3, metaverse, and play-and-earn games. The platform allows developers to easily and quickly build a fully-scalable and configurable play-and-earn economy that features asset creation engines and fully balanced player markets.
About Intoolab
Founded in 2017, Intoolab has always been technology-first, building the first production ready Dynamic Bayesian Networks intelligence that can be a milestone neurosymbolic step towards A.I. frameworks that understand the human concepts structurally and not just correlationally.
Tzager is the first Bayesian Inference A.I. framework, built for biomedical research, drug discovery, and personalized medicine with the main features being Pathway Simulations, Predictor Research/Models, and Literature Intelligence. Tzager is not just another deep learning algorithm trained to solve very specific problems, but an intelligent system with its own framework.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005121/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom